I am convinced that incorporating API (Active Pharmaceutical Ingredient) manufacture into the UK's national health strategy is not just advantageous but imperative. Recent global disruptions have sharply underscored the risks of depending too heavily on international sources for essential medical supplies. This should serve as a wake-up call for UK chemical manufacturers to strengthen domestic API production capabilities—a strategic move that would secure national health security and enhance economic stability.